Indications
This page is an informational overview of prescribing information and does not replace the full official label. Current U.S. labeling identifies ibrutinib as a kinase inhibitor indicated for adult CLL/SLL, CLL/SLL with 17p deletion, WM, and cGVHD after failure of one or more lines of systemic therapy. The current European authorization contains additional defined MCL treatment settings and differs in wording from U.S. labeling.
Dosage and Administration
For adult CLL/SLL and WM, current U.S. labeling specifies 420 mg orally once daily. For cGVHD, patients aged 12 years and older use 420 mg once daily, while patients aged 1 to under 12 years use 240 mg/m² once daily, up to 420 mg. These are label-level examples, not personalized prescriptions. The correct dose depends on the indication, formulation, interactions, and clinical circumstances.
Dosage Forms and Strengths
Current U.S. dosage forms include 70 mg and 140 mg capsules; 140 mg, 280 mg, and 420 mg tablets; and a 70 mg/mL oral suspension. Capsules are taken with water and should not be opened, broken, or chewed. Tablets should not be cut, crushed, or chewed. Suspension administration follows its own product instructions.
Warnings and Precautions
The U.S. label lists no formal contraindications, but that does not mean the medicine is suitable for everyone. Warnings and precautions include hemorrhage, infections, cytopenias, cardiac arrhythmias, hypertension, second primary malignancies, tumor lysis syndrome, and embryo-fetal toxicity. Clinical judgment is needed to balance these risks against the potential treatment benefit.
Drug Interactions
Drug interactions are particularly important. CYP3A inhibitors can increase ibrutinib exposure, while CYP3A inducers can reduce exposure and potentially reduce effectiveness. The label provides management recommendations for different interaction categories. Because interaction severity can depend on the specific medicine and indication, the patient’s full medication list should be reviewed by a healthcare professional.
Monitoring
Bleeding risk deserves special attention, especially when anticoagulants or antiplatelet medicines are involved. Infection risk and low blood counts may also require monitoring. Cardiac effects such as atrial fibrillation and atrial flutter can occur, so new palpitations, dizziness, fainting, chest discomfort, or shortness of breath should be assessed promptly.
Pregnancy and Breastfeeding
Pregnancy precautions are important because ibrutinib can cause fetal harm. Patients who are pregnant, may become pregnant, or are planning pregnancy should discuss the medicine with their healthcare professional. Breastfeeding considerations should likewise be addressed using the current label and clinical advice.
Using the Full Official Label
The full prescribing document should be consulted whenever a clinical decision is being made. This page is intended to help readers understand the structure of prescribing information: indications, dosage forms, dosing, warnings, interactions, monitoring, and reproductive precautions. It should not be treated as a stand-alone prescription resource.
Additional Practical Context
Prescribing information should be treated as a living clinical document rather than a static webpage. Regulatory agencies may revise indications, formulations, warnings, and dosage recommendations as new evidence becomes available. This is particularly relevant to ibrutinib because different jurisdictions have distinct authorization histories and because several formulations are available. Readers should check the date and jurisdiction of the document they are using. When a healthcare professional provides a current product leaflet, that document should be followed for the specific medicine dispensed.
Further Practical Context
Prescribing information should also be read in relation to formulation. The U.S. label includes capsules, tablets, and oral suspension, and each has specific administration instructions. A reader who sees “140 mg” should not assume that every 140 mg presentation can be handled in the same way. The full label also addresses dose modification for interactions and adverse reactions. These provisions are clinically important because treatment may need to continue safely despite a complication, but only the responsible clinician can determine whether an adjustment is appropriate. The website therefore summarizes the label’s structure while directing clinical decisions back to the authoritative document.
Editorial Note
Readers should verify the revision date of prescribing information when making a clinical decision, especially when a medicine has multiple formulations or jurisdiction-specific indications.
Related Information
Readers can continue to the site’s related pages on About Ibrutinib, Clinical Information, How Ibrutinib Works, Uses & Treatment, Dosage & Administration, Safety Information, Side Effects, Product Verification, and References.